Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Trial of DV700P-RNA and DV701B1.1-RNA HIV Vaccines
NCT06919016Phase 1Active, not recruiting
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Aug 2025
- Primary completion
- Mar 2027
- Modality
- RNA Therapeutics, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1 trial of DV700P-RNA and DV701B1.1-RNA in human immunodeficiency virus infection (HIV) (3 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Incidence of local reactogenicity signs and symptoms at 295 days, Incidence of systemic reactogenicity signs and symptoms at 295 days and 7 more. Started Aug 2025; status: active, not recruiting.
02
Drugs
DV700P-RNADV701B1.1-RNA
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT06919016.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06919016.